In March 2025, the company declared new strategies to get a immediate-to-purchaser offering of its Wegovy weight loss drug. The company recognized a different pharmacy, named NovoCare, which would demand prospects $499 every month for access to the drug, lower than 50 percent the cost of the drug through other pharmaceutical distribution networks.[